RT Journal Article
SR Electronic
T1 Reliable Monitoring of Respiratory Function with Home Spirometry in People Living with Amyotrophic Lateral Sclerosis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2025.02.03.25321333
DO 10.1101/2025.02.03.25321333
A1 Peller, Julián
A1 Trevisan, Marcos A
A1 Bujia, Gaston
A1 Aguirre, Felipe
A1 Shalom, Diego E.
A1 Taitz, Alan
A1 Henze, Stephanie
A1 Bastola, Silviya
A1 Osik, Jason
A1 Shewcraft, Ryan A.
A1 Jiang, Peng
A1 Schwartz, Joel
A1 Heiman-Patterson, Terry
A1 Sherman, Michael E.
A1 Wipperman, Matthew F.
A1 Levy, Oren
A1 Shou, Guofa
A1 Sillay, Karl A.
A1 Ostrow, Lyle W.
A1 Fraenkel, Ernest
A1 Berry, James D.
A1 Bingham, Indu Navar
A1 Roitberg, Esteban G.
YR 2025
UL http://medrxiv.org/content/early/2025/02/06/2025.02.03.25321333.abstract
AB Monitoring respiratory function is essential for assessing the progression of Amyotrophic Lateral Sclerosis (ALS) and planning interventions. Using spirometry data from the Radcliff Study —a fully remote, longitudinal, exploratory study with a cohort of 67 pALS—we demonstrate that flexible coaching, combined with a quality control analysis that excludes values of ‘0’ and timepoints with failed measurement trials, produces consistent remote spirometry results. Our findings indicate that home-measured Slow Vital Capacity (SVC) and Forced Vital Capacity (FVC) evolve similarly and progress linearly over the study period (7.7 ± 4.0 months). This remains true in both slow and fast progressor subpopulations. This observed linearity in respiratory trajectories supports the potential for early, accurate estimation of progression, reinforcing the feasibility of less frequent monitoring without compromising assessment precision, and reducing the burden on both pALS and the healthcare system. Furthermore, our results align with reported in-clinic pulmonary tests, validating remote monitoring as a means to promote more equitable and accessible clinical trial designs.Competing Interest StatementJP, MAT, GB, FA and DES are paid consultants to EverythingALS. AT was a paid consultant to EverythingALS. Work was done while working at EverythingALS. Currently he is an employee of SRI International. SH and SB are paid consultants to EverythingALS. JO, RAS, PJ, JS are current employees of and report equity ownership in Bristol Myers Squibb. THP is a Medical Advisory Board for Mitsubishi Tanabe Pharma America, Amylyx and Novartis. She also received Clinical Trial funding from Novartis, and Clinical Study funding from Amylyx and Mitsubishi Tanabe Pharma America. MES declares no competing interests. MFW and OL are current employees and shareholders of Regeneron Pharmaceuticals, Inc. GS is an employee of Eli Lilly & Co. and holds company stock. KAS declares no competing interests. LWO and EF declare no competing interests. JDB has research support from Rapa Therapeutics, MT Pharma of America, ProJenX, Novartis, MDA, ALS Finding a Cure, ALS Association, Association for Frontotemporal Demenia and NINDS. He has been a consultant to Alexion Pharmaceuticals, Amylyx Pharmaceuticals, Biogen, MTPA, Regeneron Pharmaceuticals, Roon, Sanofi and Trace Neuroscience. He is an unpaid scientific advisor to EverythingALS. INB is the founder of EverythingALS. EGR is a paid consultant to EverythingALS.Clinical Protocols https://www.everythingals.org/radcliffstudy Funding StatementThis study was funded by EverythingALS - Peter Cohen Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Salus IRB gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data needed to reproduce the figures in this work are available at the EverythingALS Reliable Monitoring RPFTALS Github repository.